Narcolepsy Drugs Market Significant Growth, Latest Trends, Opportunity And Forecast 2032 Report

By Author: Ellenkuhn
Total Articles: 5
Comment this article

According to a new report published by K D Market Insights, titled, “Narcolepsy Drugs Market Insights, Trends, Opportunity & Forecast, 2023–2032,” the global narcolepsy drugs market size is anticipated to witness moderate growth during the forecast period i.e., 2023-2032. The rising prevalence of narcolepsy, a chronic sleep disorder characterized by excessive daytime sleepiness and sudden episodes of sleep increasing awareness about narcolepsy, advancements in drug therapies, and the growing emphasis on improving the quality of life for affected individuals which are the major factors augmenting the growth of the global narcolepsy drugs market.
The aging population and their vulnerability to various chronic and acute diseases that require medical care. The rise in narcoleptic diseases, changing lifestyles, and the increase in stress levels, which can contribute to the development of narcolepsy disorders are further expected to create ample growth opportunities for the global narcolepsy drugs market during the forecast period i.e., 2023-2032. Moreover, advancements in medical research and development have led ...
... to the introduction of innovative and effective treatment options has propelled market expansion. Reimbursement policies incentivize patients to seek appropriate treatment, is expected to contribute towards the market growth during the period.
The North America region accounted for the largest share in the global narcolepsy drugs market in 2022. The region is further projected to continue dominating in the market and also register the highest CAGR in the market during the forecast period. This can be attributed to the high prevalence of narcolepsy and the presence of well-established healthcare infrastructure.
According to disease type, the excessive daytime sleepiness segment accounted for the largest market share in the narcolepsy drugs market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
The global narcolepsy drugs market is segmented into disease type, therapeutics type and region. Based on disease type, the market is bifurcated into daytime extreme sleepiness, cataplexia, and other disease type. Based on therapeutics type, it is classified into central nervous system stimulants, tricyclic antidepressants, sodium oxybate, selective serotonin reuptake inhibitor, and other therapeutic type.
The global narcolepsy drugs market is analyzed across North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Australia, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America) and Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, and Rest of Middle East & Africa).
Key Insights of Narcolepsy drugs Market
• On the basis of disease type, the excessive daytime sleepiness segment accounted for the largest market share in the narcolepsy drugs market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
• On the basis of region, North America accounted for the largest share in the global narcolepsy drugs market in 2022. The region is further projected to continue dominating in the market during the forecast period.
• On the basis of region, Asia-Pacific is estimated to account for the second largest share in the market during the forecast period.
Some of the major narcolepsy drugs companies profiled in the report include Teva pharmaceutical industries ltd., Takeda pharmaceutical company, Bioprojet pharma Sarl, jazz pharmaceutical plc, arena pharmaceutical, inc., Novartis international ag, Shinogi inc., and ligand pharmaceuticals incorporated.